Celltrion's anti cancer drugs hold 90% market share in C.America

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....

Celltrion establishes subsidiary in Vietnam

Celltrion Inc., South Korea’s largest biosimilar maker, said on Monday that it completed the establishment of a local subsidiary in Vietnam....

Celltrion to deliver three treatments to Peru

South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) t...

Celltrion to export three anticancer drugs to Europe

South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...

Celltrion signs largest-ever quarterly deal with global sales affiliate

Celltrion Inc., a South Korean biopharmaceutical giant, said Monday it will provide biosimilars worth 423.6 billion won ($323.6 million), its larges...

Celltrion's Truxima shows safety, efficacy in post-marketing study

South Korean biopharmaceutical company Celltrion Inc. reported on Wednesday that its biosimilar drug Truxima (rituximab), a generic version of Roche...

Celltrion acquires approval to sell Vegzelma in Canada

South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma...

Celltrion's Remsima receives approval in 100 countries in 10 years

South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...